BioClinica ApS: Financial statements 2022
CVR: 41590939
Source: annual report 2022, Danish Business Authority
01/01/2022 – 31/12/2022
BioClinica ApS (CVR 41590939) has filed annual accounts for 2022. In 2022, the company reported a gross profit of DKK -22,036 and a net result of DKK -22,672. Equity in the 2022 report amounted to DKK -70,471.
- Gross Profit
- DKK -22,036
- Profit/Loss
- DKK -22,672
- Equity
- DKK -70,471
- Total Assets
- DKK 81,566
Official annual report
Keep an eye on BioClinica ApS
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringEvents in 2022
BioClinica ApS has published its interim report for the period July 31, 2020 – December 31, 2021.
As of June 29, 2022, Michael John Bonello is registered as director of BioClinica ApS.
As of June 29, 2022, Christopher Orlando has stepped down as director of BioClinica ApS.
As of June 29, 2022, Charles R Bodner has stepped down as director of BioClinica ApS.
About BioClinica ApS
BioClinica ApS was a Danish company of the type Anpartsselskab based in København K, founded in 2020. The company has been dissolved on 26 February 2026. The company was registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. In 2024, the company reported a gross profit of DKK -63,754 and a net result of DKK -73,479 compared with DKK -24,530 the year before. Equity in the 2024 report amounted to DKK -168,480.